Abstract
A therapy gaining rapid clinical adoption involves radioembolization with the use of Yttrium-90 (90Y) microspheres. The 20–60 μm-sized microspheres are injected trans-arterially and flow to hepatic tumors given their preferential blood supply from the hepatic artery. Once they lodge in the arterioles, they impart a very intense local radiotherapeutic effect. Given the combined radiation and embolic effect, the imaging findings imparted by this mode of action differ significantly from other treatments. This work represents a comprehensive review of the imaging findings following radioembolization in patients with primary liver tumors. The report discusses imaging response, benign secondary effects, and complications. This should help educate the radiologist on imaging findings that should be expected following radioembolization and therefore aid in the proper image interpretation.
Similar content being viewed by others
References
Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108
El-Serag HB (2002) Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol 35:S72–S78
El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132:2557–2576
Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. Hepatology 42:1208–1236
Sato K, Lewandowski RJ, Bui JT, et al. (2006) Treatment of unresectable primary and metastatic liver cancer with Yttrium-90 microspheres (TheraSphere(R)): assessment of hepatic arterial embolization. Cardiovasc Intervent Radiol 29:522–529
Salem R, Thurston KG (2006) Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: part 1: technical and methodologic considerations. J Vasc Interv Radiol 17:1251–1278
Salem R, Thurston KG, Carr BI, et al. (2002) Yttrium-90 microspheres: radiation therapy for unresectable liver cancer. J Vasc Interv Radiol 13:S223–S229
Dancey JE, Shepherd FA, Paul K, et al. (2000) Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med 41:1673–1681
Russell JL, Carden JL, Herron HL (1988) Dosimetry calculations for yttrium-90 used in the treatment of liver cancer. Endocurietherapy/Hyperthermia Oncol 4:171–186
Salem R, Thurston KG (2006) Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: part 2: special topics. J Vasc Interv Radiol 17:1425–1439
Kennedy A, Nag S, Salem R, et al. (2007) Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys 68:13–23
Ibrahim SM, Lewandowski RJ, Sato KT, et al. (2008) Radioembolization for the treatment of unresectable hepatocellular carcinoma: a clinical review. World J Gastroenterol 14:1664–1669
Covey AM, Brody LA, Maluccio MA, et al. (2002) Variant hepatic arterial anatomy revisited: digital subtraction angiography performed in 600 patients. Radiology 224:542–547
Allen PJ, Stojadinovic A, Ben-Porat L, et al. (2002) The management of variant arterial anatomy during hepatic arterial infusion pump placement. Ann Surg Oncol 9:875–880
Carr BI (2002) Hepatic artery chemoembolization for advanced stage HCC: experience of 650 patients. Hepatogastroenterology 49:79–86
Chun HJ, Byun JY, Yoo SS, Choi BG (2003) Added benefit of thoracic aortography after transarterial embolization in patients with hemoptysis. AJR 180:1577–1581
Arora R, Soulen MC, Haskal ZJ (1999) Cutaneous complications of hepatic chemoembolization via extrahepatic collaterals. J Vasc Interv Radiol 10:1351–1356
Ueno K, Miyazono N, Inoue H, et al. (1995) Embolization of the hepatic falciform artery to prevent supraumbilical skin rash during transcatheter arterial chemoembolization for hepatocellular carcinoma. Cardiovasc Intervent Radiol 18:183–185
Inaba Y, Arai Y, Matsueda K, et al. (2001) Right gastric artery embolization to prevent acute gastric mucosal lesions in patients undergoing repeat hepatic arterial infusion chemotherapy. J Vasc Interv Radiol 12:957–963
Chung JW, Park JH, Han JK, et al. (1996) Hepatic tumors: predisposing factors for complications of transcatheter oily chemoembolization. Radiology 198:33–40
Therasse P, Arbuck SG, Eisenhauer EA, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216
Keppke AL, Salem R, Reddy D, et al. (2007) Imaging of hepatocellular carcinoma after treatment with yttrium-90 microspheres. AJR 188:768–775
Atassi B, Bangash AK, Bahrani A, et al. (2008) Multimodality imaging following 90Y radioembolization: a comprehensive review and pictorial essay. Radiographics 28:81–99
Kulik LM, Atassi B, van Holsbeeck L, et al. (2006) Yttrium-90 microspheres (TheraSphere(R)) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol 94:572–586
Salem R, Lewandowski RJ, Atassi B, et al. (2005) Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol 16:1627–1639
Sangro B, Bilbao JI, Boan J, et al. (2006) Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 66:792–800
Bruix J, Sherman M, Llovet JM, et al. (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35:421–430
Kulik LM, Carr BI, Mulcahy MF, et al. (2008) Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 47:71–81
Liapi E, Geschwind JF, Vossen JA, et al. (2008) Functional MRI evaluation of tumor response in patients with neuroendocrine hepatic metastasis treated with transcatheter arterial chemoembolization. AJR 190:67–73
Deng J, Miller FH, Rhee TK, et al. (2006) Diffusion-weighted MR imaging for determination of hepatocellular carcinoma response to yttrium-90 radioembolization. J Vasc Interv Radiol 17:1195–1200
Deng J, Virmani S, Young J, et al. (2008) Diffusion-weighted PROPELLER MRI for quantitative assessment of liver tumor necrotic fraction and viable tumor volume in VX2 rabbits. J Magn Reson Imaging 27:1069–1076
Kamel IR, Bluemke DA, Ramsey D, et al. (2003) Role of diffusion-weighted imaging in estimating tumor necrosis after chemoembolization of hepatocellular carcinoma. AJR 181:708–710
Sarikaya I, Bloomston M, Povoski SP, et al. (2007) FDG-PET scan in patients with clinically and/or radiologically suspicious colorectal cancer recurrence but normal CEA. World J Surg Oncol 5:64
Miller FH, Keppke AL, Reddy D, et al. (2007) Response of liver metastases after treatment with yttrium-90 microspheres: role of size, necrosis, and PET. AJR 188:776–783
Kennedy AS, Coldwell D, Nutting C, et al. (2006) Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys 65:412–425
Sato KT, Lewandowski RJ, Mulcahy MF, et al. (2008) Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres–safety, efficacy, and survival. Radiology 247:507–515
Khan SA, Davidson BR, Goldin R, et al. (2002) Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 51 Suppl 6:VI1–9
Kulik LM, Mulcahy MF, Hunter RD, et al. (2005) Use of yttrium-90 microspheres (TheraSphere) in a patient with unresectable hepatocellular carcinoma leading to liver transplantation: a case report. Liver Transpl 11:1127–1131
Lewandowski R, Salem R, Thurston K, et al. (2004) Radiation segmentectomy of unresectable of liver carcinoma using selective infusion of intraarterial Yttrium-90 theraSphere. Radiological Society of North America, Chicago
Rhee TK, Omary RA, Gates V, et al. (2005) The effect of catheter-directed CT angiography on Yttrium-90 radioembolization treatment of hepatocellular carcinoma. J Vasc Interv Radiol 16:1085–1091
Jakobs TF, Saleem S, Atassi B, et al. (2008) Fibrosis, portal hypertension, hepatic volume changes induced by intra-arterial radiotherapy with (90)Yttrium microspheres. Dig Dis Sci 53(9):2556–2563
Cherqui D, Palazzo L, Piedbois P, et al. (1994) Common bile duct stricture as a late complication of upper abdominal radiotherapy. J Hepatol 20:693–697
Nakakubo Y, Kondo S, Katoh H, et al. (2000) Biliary stricture as a possible late complication of radiation therapy. Hepatogastroenterology 47:1531–1532
Liu DM, Salem R, Bui JT, et al. (2005) Angiographic considerations in patients undergoing liver-directed therapy. J Vasc Interv Radiol 16:911–935
Sakamoto I, Iwanaga S, Nagaoki K, et al. (2003) Intrahepatic biloma formation (bile duct necrosis) after transcatheter arterial chemoembolization. AJR 181:79–87
Atassi B, Bangash AK, Lewandowski RJ, et al. (2008) Biliary sequelae following radioembolization with yttrium-90 microspheres. J Vasc Interv Radiol 19:691–697
Murthy R, Brown DB, Salem R, et al. (2007) Gastrointestinal complications associated with hepatic arterial yttrium-90 microsphere therapy. J Vasc Interv Radiol 18:553–561 quiz 62
Lewandowski RJ, Sato KT, Atassi B, et al. (2007) Radioembolization with (90)y microspheres: angiographic and technical considerations. Cardiovasc Intervent Radiol 30:571–592
Salem R, Lewandowski RJ, Sato KT, et al. (2007) Technical aspects of radioembolization with 90Y microspheres. Tech Vasc Interv Radiol 10:12–29
Ingold JA, Reed GB, Kaplan HS, Bagshaw MA (1965) Radiation hepatitis. Am J Roentgenol Radium Ther Nucl Med 93:200–208
Lawrence TS, Robertson JM, Anscher MS, et al. (1995) Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys 31:1237–1248
Sangro B, Gil-Alzugaray B, Rodriguez J, et al. (2008) Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer 112:1538–1546
Young JY, Rhee TK, Atassi B, et al. (2007) Radiation dose limits and liver toxicities resulting from multiple yttrium-90 radioembolization treatments for hepatocellular carcinoma. J Vasc Interv Radiol 18:1375–1382
Llovet JM, Beaugrand M (2003) Hepatocellular carcinoma: present status and future prospects. J Hepatol 38(Suppl 1):S136–S149
Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37:429–442
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ibrahim, S.M., Nikolaidis, P., Miller, F.H. et al. Radiologic findings following Y90 radioembolization for primary liver malignancies. Abdom Imaging 34, 566–581 (2009). https://doi.org/10.1007/s00261-008-9454-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00261-008-9454-y